Custom service

Stable Cell Line Construction

A production line that holds its titre after sixty passages.

Timeline: 10–16 weeks — to validated cloneStability: ≥60 passages — documented productivitySystems: GS, DHFR, CRISPR — knock-in options

A stable cell line is a commitment. It takes longer to build than a transient expression, costs more, and in return gives a supply of protein that does not change from batch to batch. Whether that trade is worth making depends on how long the project will run and how strictly the product must be defined.

Construction begins with the vector and the selection system. GS-mediated selection with methionine sulfoximine, or DHFR with methotrexate, allows amplification of the integrated cassette and a stepwise increase in titre. CRISPR knock-in at a defined locus offers a different advantage: a single integration site, predictable expression and no random position effects, which shortens clone screening and reduces variability.

Clonal selection is the slow part and cannot be compressed safely. After selection, single cells are deposited by limiting dilution or FACS into 96-well plates, expanded over four to six weeks, and screened for specific productivity rather than for titre in a static well. The best clones go through a stability study of at least sixty passages, because a clone that loses 30% of its productivity by passage forty is not a production cell line.

Service Highlights

Where it fits

Stable lines are built when a protein or antibody must be produced repeatedly over months or years, when the quantity exceeds what transient transfection can supply economically, or when a regulatory submission requires a defined and documented production system.

They are unnecessary for a one-off batch, for early feasibility work, and for proteins that are toxic to the host cell. In those cases transient expression is faster and cheaper, and a stable line would add months without adding value.

Documentation and QC

Each cell line is delivered with cloning documentation, growth and productivity curves, a sixty-passage stability study, sterility and mycoplasma results, and identity confirmation by STR profiling or vector-specific PCR. Master and working banks are supplied with passage numbers and viable cell counts.

Frequently asked questions

How long does it really take?

Ten to sixteen weeks from vector to validated bank: two to three weeks for transfection and selection, four to six weeks for cloning and expansion, and four to six weeks for the stability study, which can run in parallel with process development.

Pool or clone for a research reagent?

A pool is usually enough for research supply and saves six weeks. A clone is worth the time when the reagent will be used for years or when a regulator will review the process.

Can you knock the gene into a specific locus?

Yes, using CRISPR at a defined safe-harbour site. Expression is more predictable than with random integration, though titre is often lower than an amplified random integrant.

Tell us the annual quantity and the regulatory context. If the answer is a few hundred milligrams for research, a stable pool will do; if it is grams under a documented process, we will build a clone.

Service Highlights

  • Selection matched to the product. GS, DHFR or CRISPR knock-in, chosen for the titre required and the regulatory path.
  • Specific productivity screening. Clones ranked by antibody produced per cell per day, not by the titre of a static well.
  • Single-cell cloning documented. Limiting dilution with statistical monoclonality, or FACS deposition with imaging evidence.
  • Stability to 60 passages. Productivity and growth measured every ten passages, with the decay curve reported.
  • Suspension and serum-free. Adapted before banking, so the line is ready for bioreactor use.
  • Master and working banks. Two-tier banking with full documentation, sterility and mycoplasma testing.

How the work runs

  1. Host and vector design

    Host cell, selection system and expression cassette are chosen against the required titre and the regulatory path. Codon usage and signal peptide are optimised for the host.

  2. Transfection and selection

    Cells are transfected by electroporation, then selected under methionine sulfoximine or methotrexate for two to three weeks, with untransfected cells as a kill control.

  3. Pool expansion

    The surviving pool is expanded and its specific productivity measured in a small fed-batch run before cloning is attempted.

  4. Single-cell cloning

    Limiting dilution or FACS deposition into 96-well plates, with imaging evidence of single cells; clones expanded over four to six weeks and screened by productivity.

  5. Stability study

    The best clones are passaged continuously, with titre and growth measured every ten passages to sixty, and the decay curve reported.

  6. Banking

    Master and working banks prepared in serum-free medium with 10% DMSO, tested for sterility and mycoplasma, and stored in vapour-phase nitrogen.

Specifications & timeline

Timeline
10–16 weeks — to validated clone
Stability
≥60 passages — documented productivity
Systems
GS, DHFR, CRISPR — knock-in options
Host
CHO-K1, CHO-S, HEK293, NS0
Selection systems
GS/MSX, DHFR/MTX, puromycin, CRISPR knock-in at a safe-harbour locus
Scale
From a 1 L shake flask to a 50 L bioreactor
Titre
0.5–5 g/L after amplification, host-dependent
Stability
≥60 passages with productivity and growth documented
Timeline
10–16 weeks from vector to validated bank
Deliverables
Clonal line, master and working banks, stability data, cloning documentation, STR identity

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.